Can I read Current and Emerging Biologic Therapies Targeting Eosinophilic Disorders on EtoBox?

Current and Emerging Biologic Therapies Targeting Eosinophilic Disorders by Mitchell M. Pitlick; James T. Li; Thanai Pongdee is a Medicine article available to read on EtoBox.

What is Current and Emerging Biologic Therapies Targeting Eosinophilic Disorders about?

Eosinophilic disorders include a wide array of conditions in which eosinophils play a primary pathophysiologic role. While historically treated with corticosteroids and immunosuppressants, knowledge of eosinophil biology has led to the development of several biologics targeting eosinophils. In this review, we discuss the current US Food and Drug Administration (FDA) approved eosinophil-specific biologics targeting IL-5 (mepolizumab and reslizumab) and IL-5R (benralizumab) along with biologics under investigation targeting siglec-8 (lirentelimab). We discuss efficacy and safety data from trials of these medications in conditions including eosinophilic asthma, hypereosinophilic syndrome (HES), eosinophilic granulomatosis with polyangiitis (EGPA), chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis (EoE), and eosinophilic gastrointestinal disease (EGID). Additionally, we discuss case reports utilizing these medications in conditions including drug reaction with eosinophilia and systemic symptoms (DRESS), allergic bronchopulmonary aspergillosis (ABPA), and eosinophilic pneumonia, among others. While eosinophilic targeting biologic therapy has been successful

Who reads Current and Emerging Biologic Therapies Targeting Eosinophilic Disorders?

Author

Mitchell M. Pitlick; James T. Li; Thanai Pongdee

Publisher

Elsevier BV

Published

2022

Language

EN

Field

Medicine (Health Sciences)